13F-HR: Gilead Sciences Q3 2025 Equity Holdings Disclosure

Gilead Sciences, Inc. reported its institutional equity holdings for the quarter ended September 30, 2025, totaling $1.79 billion across nine positions.

Summary

• Gilead Sciences, Inc. submitted its Form 13F-HR, a quarterly report detailing its institutional equity holdings.
• The report covers the calendar quarter ended September 30, 2025, and was signed on November 13, 2025.
• The total market value of reported holdings amounts to $1,791,467,184.
• The filing includes 9 distinct holdings entries.
• Gilead Therapeutics A1 Unlimited Co is listed as an included manager in this report.
• Key holdings include common stock in ARCELLX INC, ARCUS BIOSCIENCES INC, ASSEMBLY BIOSCIENCES INC, GALAPAGOS NV, TANGO THERAPEUTICS INC, KYVERNA THERAPEUTICS INC, XILIO THERAPEUTICS INC, LEAP THERAPEUTICS INC, and MERUS N V.
• All reported holdings show sole investment discretion and sole voting authority, with the exception of GALAPAGOS NV, which lists 'DFND 1' for investment discretion.

Sentiment

Score: 5

Explanation: The filing is a routine regulatory disclosure of historical equity holdings, providing factual information without indicating positive or negative performance for the reporting entity.

Positives

• Provides transparency into Gilead Sciences' institutional equity investment strategy.
• Fulfills regulatory disclosure requirements set by the U.S. Securities and Exchange Commission.

Negatives

• Represents a backward-looking snapshot of holdings as of September 30, 2025, and does not reflect current portfolio changes.
• Does not provide insights into the rationale behind investment decisions or future investment strategy.
• Lacks information on the performance of the underlying investments or the reporting manager's overall financial health.

Risks

• This filing does not contain specific risk factors related to Gilead Sciences, Inc.'s operations or financial condition.
• The listed equity holdings are subject to market risks, including volatility, liquidity risk, and company-specific risks, which are not detailed in this disclosure.

Future Outlook

This filing is a historical disclosure of equity holdings and does not contain any forward-looking statements or guidance regarding future performance or investment strategy.

Management Comments

• Andrew D. Dickinson, Executive Vice President and Chief Financial Officer, signed the report, affirming its truth, correctness, and completeness on behalf of Gilead Sciences, Inc.

Industry Context

Form 13F-HR filings are standard quarterly disclosures for institutional investment managers with over $100 million in equity assets. Gilead Sciences, a major biopharmaceutical company, primarily holds stakes in other biotechnology and pharmaceutical firms, aligning with its core industry focus and potential strategic interests.

Comparison to Industry Standards

• This is a standard regulatory disclosure for institutional investment managers, providing a snapshot of equity holdings.
• The nature and composition of the portfolio, heavily weighted towards biotechnology and pharmaceutical companies, are consistent with the strategic investment patterns observed in the biopharmaceutical industry, often reflecting strategic partnerships, venture investments, or R&D collaborations.
• Specific comparisons to other companies' 13F filings would require detailed analysis of their respective portfolios, which is beyond the scope of this filing.

Related Party Transactions

• Gilead Therapeutics A1 Unlimited Co is listed as an 'Other Included Manager' with Form 13F File No. 028-25083, indicating a relationship with the reporting manager, Gilead Sciences, Inc. This filing does not detail specific transactions between these entities.

Stakeholder Impact

• Shareholders: Provides transparency into a portion of the company's investment portfolio, offering insights into its strategic investments in other public companies.
• Regulatory Authorities: Fulfills SEC disclosure requirements, ensuring compliance and market transparency.
• Investment Community: Offers data for analysts and investors to track institutional investment trends and potential strategic alignments within the biotechnology sector.

Next Steps

• This filing does not outline any specific future actions, events, or milestones for Gilead Sciences, Inc.

Key Dates

Keywords

Gilead Sciences, 13F-HR, Equity Holdings, Institutional Investment, Portfolio Disclosure, Biotechnology Investments, Pharmaceutical Sector, Q3 2025 Holdings